Compare Stocks: ATOS, DTSQ, ANIX, and ACRV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$2.00 -2.0%	$1.89	$1.27 ▼ $3.56	$85.71M	1.92	340,678 shs	461,585 shs
ANIX Anixa Biosciences	$2.76 +0.4%	$3.33	$2.32 ▼ $5.46	$95.95M	0.51	309,138 shs	389,132 shs
ATOS Atossa Genetics	$2.51 +7.3%	$2.44	$1.70 ▼ $19.35	$25.05M	1.27	54,964 shs	58,613 shs
DTSQ DT Cloud Star Acquisition	$11.44 +0.7%	$11.35	$10.45 ▼ $12.90	$101.34M	-0.01	705 shs	1,770 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-1.96%	-6.10%	+16.28%	+35.14%	+22.70%
ANIX Anixa Biosciences	+0.36%	-10.10%	-14.55%	+11.74%	-8.61%
ATOS Atossa Genetics	+7.26%	-0.40%	+6.81%	+2.03%	-79.04%
DTSQ DT Cloud Star Acquisition	+0.43%	+0.66%	+1.14%	+1.54%	+9.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$2.00 -2.0%	$1.89	$1.27 ▼ $3.56	$85.71M	1.92	340,678 shs	461,585 shs
ANIX Anixa Biosciences	$2.76 +0.4%	$3.33	$2.32 ▼ $5.46	$95.95M	0.51	309,138 shs	389,132 shs
ATOS Atossa Genetics	$2.51 +7.3%	$2.44	$1.70 ▼ $19.35	$25.05M	1.27	54,964 shs	58,613 shs
DTSQ DT Cloud Star Acquisition	$11.44 +0.7%	$11.35	$10.45 ▼ $12.90	$101.34M	-0.01	705 shs	1,770 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-1.96%	-6.10%	+16.28%	+35.14%	+22.70%
ANIX Anixa Biosciences	+0.36%	-10.10%	-14.55%	+11.74%	-8.61%
ATOS Atossa Genetics	+7.26%	-0.40%	+6.81%	+2.03%	-79.04%
DTSQ DT Cloud Star Acquisition	+0.43%	+0.66%	+1.14%	+1.54%	+9.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	575.00% Upside
ANIX Anixa Biosciences	2.40	Hold	$10.00	262.32% Upside
ATOS Atossa Genetics	2.20	Hold	$20.33	710.09% Upside
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATOS, DTSQ, ANIX, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/30/2026	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
ANIX Anixa Biosciences	$210K	456.85	N/A	N/A	$0.38 per share	7.26
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ATOS, DTSQ, ANIX, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
ANIX Anixa Biosciences	N/A	8.55	9.79
ATOS Atossa Genetics	N/A	5.69	5.14
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ANIX Anixa Biosciences	29.13%
ATOS Atossa Genetics	12.74%
DTSQ DT Cloud Star Acquisition	N/A

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
ANIX Anixa Biosciences	26.40%
ATOS Atossa Genetics	9.80%
DTSQ DT Cloud Star Acquisition	52.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	42.85 million	38.35 million	Not Optionable
ANIX Anixa Biosciences	5	34.76 million	25.04 million	Optionable
ATOS Atossa Genetics	8	9.98 million	9.00 million	Optionable
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A

ATOS, DTSQ, ANIX, and ACRV Headlines

Recent News About These Companies

DT Cloud Star Acquisition Corporation (NASDAQ:DTSQ) Short Interest Down 32.4% in August

September 1, 2026 | marketbeat.com

DT Cloud Star SPAC Extends Business Combination Deadline

August 25, 2026 | tipranks.com

DT Cloud Star Relocates Principal Executive Office to Jersey City

August 19, 2026 | tipranks.com

DT Cloud Star Acquisition Corporation (NASDAQ:DTSQ) Short Interest Down 57.6% in July

August 15, 2026 | marketbeat.com

DT Cloud Star Faces Nasdaq Delisting Amid Compliance Issues

July 20, 2026 | tipranks.com

DT Cloud Star Announces Board Director Resignation

April 10, 2026 | tipranks.com

DT Cloud Star Faces Nasdaq Public Holder Deficiency Notice

April 9, 2026 | tipranks.com

DT Cloud Star to Merge with PrimeGen US

February 4, 2026 | tipranks.com

DT Cloud Star SPAC Extends Deadline for Business Combination

January 7, 2026 | tipranks.com

DT Cloud Star Acquisition Cancels Planned Shareholder Meeting

December 22, 2025 | tipranks.com

DT Cloud Star Adjourns Shareholder Meeting to December 22

December 15, 2025 | tipranks.com

DT Cloud Star Appoints Dr. Zhou as Director

November 28, 2025 | tipranks.com

DT Cloud Star Approves Business Combination Extension

October 24, 2025 | tipranks.com

DT Cloud Star Adjourns Shareholder Meeting to October 22

October 20, 2025 | tipranks.com

DT Cloud Star Schedules Shareholder Meeting Adjournment

October 15, 2025 | tipranks.com

DT Cloud Star Meeting Adjourned to October 15

October 8, 2025 | tipranks.com

DT Cloud Star Terminates Promissory Note Agreement

July 31, 2025 | tipranks.com

DT Cloud Star Appoints Sam Zheng Sun as CEO

April 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATOS, DTSQ, ANIX, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$2.00 -0.04 (-1.96%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 09/11/2026 07:30 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Anixa Biosciences NASDAQ:ANIX

$2.76 +0.01 (+0.36%)

As of 09/11/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Atossa Genetics NASDAQ:ATOS

$2.51 +0.17 (+7.26%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.44 -0.07 (-2.91%)

As of 09/11/2026 07:59 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.44 +0.08 (+0.70%)

Closing price 09/11/2026 03:06 PM Eastern

Extended Trading

$11.44 +0.00 (+0.01%)

As of 09/11/2026 07:30 PM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATOS, DTSQ, ANIX, and ACRV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATOS, DTSQ, ANIX, and ACRV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATOS, DTSQ, ANIX, and ACRV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATOS, DTSQ, ANIX, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Anixa Biosciences NASDAQ:ANIX

Atossa Genetics NASDAQ:ATOS

DT Cloud Star Acquisition NASDAQ:DTSQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATOS, DTSQ, ANIX, and ACRV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATOS, DTSQ, ANIX, and ACRV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATOS, DTSQ, ANIX, and ACRV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATOS, DTSQ, ANIX, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Anixa Biosciences NASDAQ:ANIX

Atossa Genetics NASDAQ:ATOS

DT Cloud Star Acquisition NASDAQ:DTSQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools